AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
BIOMERICA INC
XNAS · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001S5P8X4
1.68▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.68
Day's Range
1.66 – 1.72
52-Week Range
1.45 – 3.09
Volume
12.0K
Avg Volume
20.6K
Share Statistics
Shares Outstanding
Employees
54
Exchange
XNAS
Listed
1978-09-26
Share count as of October 15, 2026

BIOMERICA INC (BMRA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about BIOMERICA INC (BMRA)
What is BIOMERICA INC's Market Cap?
BIOMERICA INC's Market Cap is $7.7M, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's Enterprise Value?
BIOMERICA INC's Enterprise Value is $5.0M, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's Price / Sales?
BIOMERICA INC's Price / Sales is 1.8×, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's EV / Revenue?
BIOMERICA INC's EV / Revenue is 1.2×, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's EV / EBITDA?
BIOMERICA INC's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's Revenue (TTM)?
BIOMERICA INC's Revenue (TTM) is $4.3M, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's Net Income (TTM)?
BIOMERICA INC's Net Income (TTM) is -$5.0M, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's EBITDA?
BIOMERICA INC's EBITDA is -$5.4M, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's Diluted EPS (TTM)?
BIOMERICA INC's Diluted EPS (TTM) is -1.09, based on as-reported figures from SEC (XBRL) filings.
What is BIOMERICA INC's EBITDA Margin?
BIOMERICA INC's EBITDA Margin is -123.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BMRAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemAug 31, 2026May 31, 2026Feb 28, 2026Nov 30, 2025Aug 31, 2025May 31, 2025Feb 28, 2025Nov 30, 2024Aug 31, 2024May 31, 2024Feb 29, 2024Nov 30, 2023Aug 31, 2023May 31, 2023Feb 28, 2023Nov 30, 2022
Revenue
YoY growth-8.3%+16.8%-11.8%-26.0%
Cost of sales
Gross profit
% of revenue8.1%-8.1%-4.5%4.2%
Operating expenses:
Selling, General and Administrative Expense
Research and Development Expense
Total operating expenses
% of revenue105.1%167.1%127.1%117.7%
Loss from operations
% of revenue-97.0%-175.2%-131.5%-113.5%
Other income:
Net Interest Income——
Total other income
(Loss) income before income taxes
Provision for income taxes
Net (loss) income
% of revenue-97.4%-130.9%-132.9%-109.1%
Earnings Per Share (Basic)
Earnings Per Share (Diluted)
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment
Comprehensive (loss) income